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ABSTRACT
Cancer cachexia is a wasting syndrome characterized by extreme weight and skeletal muscle loss
that results in death in many tumor bearing individuals. Because skeletal muscle requires a high
amount of energy to function, skeletal muscle fiber cells need healthy mitochondria to function.
When skeletal muscle loss atrophy occurs, the mitochondrial network is degraded. Different
treatments for this muscle atrophy are being studied, one of which is a leucine supplementation
since leucine has been found to stimulate skeletal muscle growth in other studies. However, current
data suggests that a leucine supplementation in cachexic individuals exacerbates this atrophy.
PURPOSE: This study will examine how leucine supplementation will affect the mitochondrial
markers in pre-cachectic mice. METHODS: Female APCMin/+ and their wild-type litter mates
were assigned to either the leucine supplementation group, which will receive leucine in their water
until tissue harvest, or no leucine supplementation group. The gastrocnemius was harvested at 13
weeks (pre-cachectic stage). Quantitative PCR was performed to determine mRNA abundance of
OPA1 and BNIP3. A two-way ANOVA was used to analyze the data. RESULTS: There were no
significant differences between in mitochondrial markers, OPA1 and BNIP3, between groups.
There was a main effect of leucine and time, and there was an interaction between genotype and
time. There were no significant differences in tissue weights, and the APCMin/+ leucine group had
the highest average polyp count. There was an interaction between genotype and treatment in peak
torque averages, and the comparison between wild-type no leucine and APCMin/+ no leucine was
significant. CONCLUSIONS: Leucine does not have a significant effect on the mitochondrial
quality or health of female mice in the pre-cachectic stage.

KEY WORDS: Leucine Supplementation, Mitochondrial Markers, Cancer Cachexia
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CHAPTER I
INTRODUCTION
Cancer is the second leading cause of death in the world and is responsible for almost 10
million deaths each year 1. One symptom associated with many cancer related deaths is a condition
called cancer cachexia. Cancer cachexia, observed in approximately 80% of cancer cases, is the
irreversible wasting syndrome that is characterized by skeletal muscle loss in an individual 2. This
skeletal muscle loss, also called skeletal muscle atrophy, leads to extreme loss of body weight and
eventually death once 25-30% of the total body weight has been lost 2. This makes cancer cachexia
responsible for up to 40% of all cancer related deaths 3. Various nutraceuticals are currently being
studied as potential treatments for skeletal muscle atrophy. One promising nutraceutical is leucine.
Leucine is one of the three branched chain amino acid (BCAA) that make up almost one
third of muscle protein. Leucine has been found to stimulate protein synthesis in skeletal muscle
by acting as a mediator for the activities of the intracellular kinase mammalian target of rapamycin
(mTOR) which influences protein translation 3,4. A balance between protein synthesis and protein
degradation within the skeletal muscle cells is what maintains skeletal muscle mass. When this
balance is altered and protein degradation exceeds protein synthesis, skeletal muscle atrophy
results. Finding a treatment to stimulate protein synthesis in cancer cachectic individuals where
this balance is interrupted could be an attractive target in reducing skeletal muscle atrophy.
Skeletal muscle is a high demand tissue and accounts for most of one’s daily energy
consumption to support its growth and function 5. To effectively take up energy, the skeletal
muscle cells require good mitochondrial quality since mitochondria produce the ATP that drives
these energy processes. Mitochondrial quality is the overall health and general function of the
mitochondrial network in the muscle 6. When a factor, such as cancer cachexia, negatively effects
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this network, degeneration of the mitochondria occurs which can induce skeletal muscle atrophy
as the cancer cachexia progresses 6. This idea is supported by recent data showing that
mitochondria quality does, indeed, decline with cancer cachexia
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. While a leucine

supplementation is being studied as a possible remedy, there have been a few drawbacks.
A recent study indicated a positive response in skeletal muscle regeneration to a leucine
supplementation after exercise 3. This led to the hypothesis that a leucine supplementation could
reduce skeletal muscle atrophy. However, our lab has preliminary data suggesting leucine
supplementation in cancer cachectic mice exacerbates skeletal muscle atrophy rather than
suppresses it during tumor progression 7. The cause of this exacerbation is unknown.
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CHAPTER II
LITERATURE REVIEW
Cancer is the second leading cause of death in the world 1. Cachexia, the wasting syndrome
characterized by loss of weight and muscle mass over time, is a key indicator of cancer in
individuals and is the leading cause of death in cancer patients 8. Previous research has shown that
cachexia induced by cancer is a multifactorial wasting syndrome. This indicates that the muscle
wasting is a product of different factors associated with the growing tumor, rather than the result
of only one element. Some of these other common factors that have been shown to aid inducing
cachexia in cancer patients are asthenia, anorexia, and anemia. 2
Asthenia is used to describe physical weakness or lack of energy. The Resting Energy
Expenditure (REE) is used to predict the 24-hour energy expenditure of an individual by using
indirect calorimetry. This helps calculate a percentage of total energy loss from the REE, which is
correlated with levels of asthenia. Research has shown that REE in cancer patients varies
depending on the malignancy type, but it typically higher in cancer patients compared to healthy
individuals. One reason for this increase is attributed to increased thermogenesis in skeletal muscle
and brown adipose tissue (BAT). Cachectic patients are shown to have more brown adipose tissue
than healthy controls, providing a potential explanation for increased thermogenesis. 2
Anorexia is another common factor in cachectic patients. Anorexia is the loss of appetite
or desire to eat, which leads to extreme weight loss. In cancer induced anorexia, the patient has a
decreased taste and smell of food, as well as having their metabolic rate altered so they experience
early satiety. Researchers believe this is done by either a physical obstruction in the GI tract from
the tumor, or the alteration of cholecystokinin (CCK) and their receptors, which are satiety
inducing peptides, in cachectic patients. Cancer induced anorexia can also be traced to the
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production of cytokines by the cancer cells. Cytokines support the growth of new tissue and blood
vessels, creating a suitable environment for cancer cells, as well as transport substances that
interact with normal endothelial cells in the body, mediating anorexia in the patient. Additionally,
in cachectic patients, a substance called anemia inducing substance (AIS) is secreted by the cancer
cells, which causes red blood cells to be osmotically fragile and reduce their deformability, as well
as depresses immune functioning cells. AIS binds to the surface of RBCs and lowers its glucose
influx and pyruvate kinase activity, leading to the dysfunction and lysis of the RBCs. The lysis of
the RBCs leads to the onset of anemia in cachectic patients.2
Cancer cachexia depletes the nutritional resources throughout the body, specifically in the
adipose tissue and skeletal muscle, because of the anemia, anorexia, and loss of energy
expenditure. This compromises the body’s ability to fight infections and eventually leads the
individual to be too weak to withstand chemo and radiation therapy, exacerbating the loss of the
body weight. Once 25-30% of the individual’s total body weight is lost, the patient dies 2. While
cancer cachexia creates similar symptoms in patients affected, there are different models used
when studying the effects of cancer cachexia.
With cachexia studies, generating clinical trials are difficult. The use of animal models has
helped alleviate this difficulty and allowed researchers to study specific diseases, potential
treatments, and new therapy regimens in more depth. Mice and rats specifically, have been shown
to be popular models utilized in research involving cancer and its resulting symptoms. While there
are many positives to using a mouse model in cancer cachexia studies, there are also some negative
aspects that researchers must keep in mind. 9
Animal models, specifically mice which are commonly used, provide effective ways to
stimulate the muscle wasting that occurs in cancer cachexia, while controlling for different
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variables, and monitoring the outcomes of treatments being studied. The mice models can be
implanted with different tumor lines where the tumor(s) can grow to a certain burden before
euthanizing the animal. For cachexia, the most common line used in models is Lewis Lung
Carcinomas, but other lines such as C26 colorectal carcinomas, prostate tumors, and colon
adenocarcinomas are also used depending on the project. The effects of these tumors in mice mimic
the reactions to those tumors in humans, allowing researchers to observe the symptoms over the
course of the experiment as well as test potential treatments. This allows for the generalizability
of certain treatments and better understanding of the pathophysiology of different tumor cell lines.
Different protocols are used for different tumor lines ensure that the experiments are ethical, and
the mice aren’t allowed to reach a point of suffering 9. In this study, APCmin/+ mice will be used.
The APCmin/+ mouse is an animal model with a mutation in the adenomatous polyposis coli (APC)
gene, so the gene is eliminated in the mice. The APC gene prevents the formation of colon cancer,
so this mutation causes the mice to develop tumors, also known as polyps, within their colon. In
many cases of human colon cancer, the APC gene is mutated, so these mice models are good to
use in studying this line of cancer. The APCmin/+ mice also display several of the same symptoms
and characteristics as humans when the tumor burden increases, so results found in these animal
studies can be generalized to human cases regarding colon cancer and muscle wasting. 10
While there are many pros to using mice models when studying cancer cachexia,
researchers must keep in mind a few potential drawbacks. One being that due to the complexity of
cachexia and many factors that influence it, completely replicating it as it appears in humans is a
challenge, and studies have shown where most tumor lines that are implanted in mice don’t
metastasize as they do in humans. Additionally, the differences between male and female growth
responses in mice can make generalizability to humans difficult, and metabolic differences
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between mice and humans can limit conclusions as many human cancer patients have other
comorbidities over several years that can’t be replicated with mice
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. Despite these drawbacks,

though, there are enough similarities between rodents and humans to justify the use of rodent
models in studies regarding cancer cachexia.
Leucine is one of three branched-chain amino acids (BCAA), the other two being
isoleucine and valine. Leucine has a predominating pH of 7.4, and contains an amino group,
carboxyl group, and a side chain consisting of a branched, nonpolar hydrocarbon group. The
BCAAs are considered an essential part of the human diet, as the body doesn’t naturally produce
them, and they make up roughly one third of muscle protein, with leucine being about 5-10% of
the protein content. Metabolism of BCAAs is initiated in skeletal muscle, and leucine specifically
has been shown to stimulate protein synthesis in the muscle. In combination with the other BCAAs,
leucine supplementation was correlated with a decrease in skeletal muscle protein degradation as
well, which is a key aspect of muscle wasting in cancer cachexia. 3
A study done on the muscle protein mass in elderly men showed that an added leucine
supplementation improved the muscle protein fractional synthesis rate and reduced the breakdown
rate. The researchers found that the BCAAs, especially leucine, were most efficient at stimulating
protein synthesis. Leucine, on its own, was able to stimulate muscle protein synthesis to the same
extent as the other amino acids. However, researchers were unable to find an effect of leucine on
whole body protein turnover. 4
The amino acid, leucine, affects protein balance by targeting the protein synthetic pathways
within the skeletal muscle. Leucine inhibits certain transcription factors like FOXO3a to prevent
the degradation of proteins and can stimulate the synthesis by producing a higher p-mTOR content,
which is a protein that controls skeletal muscle signaling. However, evidence suggests that leucine
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supplementation affects the skeletal muscle regeneration protein levels differently in aged vs
young mice. In aged mice, the added leucine resulted in an increase in relative and phosphorylated
mTOR levels. But in young mice, higher mTOR levels were found in the injured mice, regardless
of the status of an added leucine supplementation. Additionally, FOXO1 (a transcription factor for
Atrogin-1 and MuRF-1) and Atrogin-1 levels, which are atrophy markers, were found to not be
affected by leucine in young mice. The researchers concluded that while leucine has been shown
to help reduce injury-induced inflammation, in terms of protein levels a leucine supplementation
acts independently of the mTOR pathway in young mice, but dependently of the mTOR pathway
in aged mice. In other words, in young mice, leucine had no significant effect on the stimulation
of protein synthesis, and therefore the growth, of skeletal muscle. In aged mice however, leucine
directly stimulated the pathway that controls muscle growth and regeneration. On the mRNA
levels of FoxO, MuRF-1 (another atrophy marker protein), and Atrogin-1 specifically, leucine
exhibited no effect in young mice, but appeared to stop the increase of FOXO3 after injury in aged
mice 7. This data suggests that aged muscles are more sensitive to a leucine supplementation during
muscle regeneration.
Regarding muscle loss and muscle regeneration, most of this activity happens within the
skeletal muscle. Skeletal muscle is made up of three types of muscle fibers: type 1, type 2a, and
type 2b. Type 1 fibers are slow twitch fibers. They are the smallest of the muscle fiber types,
contract with low force, produce low power, and have a very high mitochondrial density. They are
the most resistant to fatigue and are mainly used in aerobic activity such as distance running. Type
2a and type 2b are fast twitch fibers. Type 2a fibers are larger than type 1 fibers, but smaller than
type 2 fibers. They contract with intermediate force, produce intermediate power, and have a high
mitochondrial density. Type 2a fibers are quick to fatigue and are mainly used in long term
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anaerobic activity such as weightlifting. Type 2b fibers are the largest fiber type. They contract
with high force, have the higher power, and a low mitochondrial density. These fibers are used in
short term anaerobic activity. Type 2b muscle fibers are the quickest to fatigue and are found in
most animal models used in research, but they are not found in humans. However, humans have a
type 2x fiber that performs similarly to type 2b. 12
Typical muscles used for observing skeletal muscle atrophy in cancer cachexia studies are
the gastrocnemius, the soleus, the tibialis anterior, the extensor digitorum longus (EDL) and the
plantaris. Cross sectional area of these muscles is used to compare cachectic patients to healthy
patients, and each muscle has different metabolic and contractile properties, allowing the
researchers to have a variety of data from different factors. Some studies suggest that a shift from
slow to fast fiber types, and therefore a higher force production, may occur during cancer cachexia
to compensate for the decrease in muscle mass from skeletal muscle atrophy. Previous animal
studies show that the type 2 muscle fibers may be more prone to atrophy indicating that type 2
fibers are targeted and are more sensitive in states of cachexia. In addition, it has been found that
this cachexia and subsequent skeletal muscle mass reduction is due to a decrease in muscle fiber
size, rather than a decrease in the number of muscle fibers 8.
Skeletal muscle generates force for movement and posture maintenance. When the muscle
atrophies, it prevents the muscle from being able to generate force to its full capacity. In cancer
cachectic patients, the maximum force contraction is decreased in several muscles compared to
health patients, as well as the cachectic patients having a weakened grip strength. While this
reduction in force and increase in muscle fatigue is mainly attributed to a decrease in fiber size,
some evidence suggests that contractile dysfunction and an impairment in calcium handling within
the fibers are also responsible for the change in patients with cachexia. Muscle contraction
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produces the muscle force, and it relies on calcium to activate the cross-bridge cycle and generate
the contraction. In cases of cachexia, the fibers may have a change in calcium sensitivity, causing
the ability of the muscle to contract to be dysfunctional, leading to changes in the generated force8.
A major factor contributing to the correct functionality of skeletal muscle is the mitochondria and
its ability to produce ATP via oxidative phosphorylation during muscle contraction.
The mitochondria is an organelle within cells that is responsible for oxidative metabolism.
Oxidative phosphorylation is the process that generates ATP from the consumption of oxygen and
movement of electrons down the mitochondrial electron transport chain. Mitochondrial
degeneration occurring within muscle cells can impair energy production, ultimately leading to
muscle atrophy. Mitochondria degeneration is a common occurrence in cachectic individuals, and
many researchers believe that mitochondrial degeneration is a critical step in the development of
the cachexia. 6
Mitochondrial degeneration results from poor mitochondrial quality. Mitochondrial quality
is the general health and function of the mitochondrial network within cells. This quality can be
measured by testing the mitochondrial oxygen consumption (VO2) from sampled fiber bundles.
Since mitochondria rely on oxygen consumption, the amount of oxygen being consumed and used
can tell the health of the mitochondria within the muscle samples. When the quality of the
mitochondria is poor, it can lead to impaired ATP production as well as excessive production of
mitochondrial reactive oxygen species (ROS), which damage the cell’s health.13 These reactive
oxygen species can allow the development of cancer cachexia. The amount of ROS produced can
also be measured to determine if the mitochondrial function is poor by sampling the fibers and
using a method that converts the ROS into a red fluorescent oxidation product. 6
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In skeletal muscle specifically, there are several processes utilized by the mitochondria to
regulate the production of ROS and manage damaged mitochondria, such as biogenesis of new
mitochondrial components and fusion or fission of mitochondrial regions within the network. In
cancer cachexia, however, these regulatory processes are impaired, which allows the
mitochondrial network to be degraded and the muscle to atrophy with the progression of the cancer
6

. These various mitochondrial processes can be indicated by mitochondrial markers such as

BNIP3, OPA1, COX4, MFN2, TFAM, and CRMP1. The levels of these markers can indicate the
health of the mitochondria.
In a recent study looking at the mitochondrial degeneration before cancer cachexia,
researchers found that the mitochondrial biogenesis was dysregulated. This was indicated by
almost a 50% decrease in mRNA contents that serve as biogenesis regulators of mitochondria,
before the cachexia occurred. They observed that the mitochondria content 4 weeks post tumor
implantation, was lower. Additionally, the mitochondrial ROS production 1 week post tumor
implantation, was 2-fold greater and remained elevated. 6
They found there was increased mitochondrial oxidative stress followed by mitochondrial
degeneration and loss of function in the muscle cells prior to the onset of muscle atrophy in the
tumor bearing mice. Amounts of biogenesis (marked by levels of Pgc-1a and Ppara), fusion
(marked by levels of Mfn2), and mitophagy (marked by levels of Bnip3) markers indicated that
the mitochondrial quality impairment begins with downregulated biogenesis and fusion regulators.
This was followed by an upregulation of mitophagy regulators. Mitophagy is the self-degradation
of mitochondria. Fis1, a marker for the number of fragmented mitochondria, was also upregulated6.
Fragmented mitochondria cannot generate ATP. Without the generation of ATP, the cell is
put under significant oxidative stress. This could be contributed to the observed decrease in muscle
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mass in tumor bearing mice. The researchers explained that this data supports the notion that
mitochondrial network degeneration and dysfunction occurs before cancer cachexia. 6
In the same study, the researchers found that damaged mitochondria directly promote
atrophy signaling in skeletal muscle and is a result of the tumor environment. Inflammation,
reduced protein synthesis, increased protein catabolism, and altered myogenesis lead to increased
ROS production and the loss of normal mitochondrial function in cancer individuals. Oxidative
stress from the damaged mitochondria leads to skeletal muscle wasting, further supporting that
mitochondrial dysregulation occurs before the onset of cancer cachexia, and that muscle
mitochondria are a key target of the cancer resulting in cancer-induced muscle wasting. 6
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CHAPTER III
PRELIMINARY DATA AND SPECIFIC AIMS
Body mass data is presented in Figure 1. Body mass increased in all groups from 6 to 20 weeks
except for the APCMin/+ leucine group. APCMin/+ group increased body mass up to week 12. We
did note a lower body mass in the APCMin/+ leucine group compared to the other groups starting at
week 14. At 20 weeks there was no effect of leucine supplementation on body mass of wild-type
mice. At 20 weeks the APCMin/+ leucine group had a lower body mass than all other groups. In
conclusion, leucine supplementation exacerbated body mass wasting in male APCMin/+ mice.

Figure 1- Body mass changes in APCmin/+ leucine male mice.

Purpose and Hypothesis
The purpose of this study was to evaluate the effects of a leucine supplementation on mitochondrial
markers in pre-cachectic, female mice.

We hypothesized that a leucine supplementation would exacerbate the decline of mitochondrial
quality in the female mice prior to the onset of cancer cachexia.
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CHAPTER IV
METHODS
Animals
We used female APCMin/+ mice bred on a C56BL/6 background that we purchased from Jackson
Laboratory (Bar Harbor, ME) and bred at the University of Arkansas. Approval was obtained from
the University of Arkansas Institutional Animal Care and Use Committee. These mice were
genetically predisposed for the development of colorectal adenomas starting at 4 weeks of age,
and therefore make for an excellent model of colon cancer and associated wasting throughout their
lifespan. All mice were given standard rodent chow and access to water ad libitum and kept on a
12h:12h light/dark cycle. Following weaning, mice were split into 4 groups based on their
genotype (Wild-type (WT) or APCMin/+), condition, and assignment to a leucine (L) or no-leucine
(NL) supplementation as shown in Figure 2. Food and water consumption were weighed weekly
in conjunction with body weight measurements across all groups.

Figure 2- Schematic of group breakdown for experiment.
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Leucine Supplementation
Following weaning, mice in the leucine supplementation groups were given leucine in their water
at a dose of 1.5g/100 mL as previously described

7,14

, with NL counterparts receiving the same

water source but without leucine enrichment.

Electrophysiology
Electrophysiology protocol was performed as previously described 6. Mice were anaesthetized and
the peroneal nerve innervating the TA was stimulated at 10, 20, 40, 60, 80 100, 125, 150, 200, 250,
and 300Hz with 400 ms pulse to induce peak tension. 11 measurements were taken, and 60 seconds
of rest were allowed between each measurement.

Tissue Harvest
The gastrocnemius, EDL, soleus, plantaris, tibialis anterior muscles were extracted along with the
heart, liver, spleen, fat, and tibia as previously described
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. The tissues were immediately flash

frozen in liquid nitrogen and stored in -80°C for mRNA abundance analysis. Mice were euthanized
via exsanguination by removal of the heart.

RNA isolation, cDNA Synthesis, and quantitative Real Time Polymerase Chain Reaction
RNA isolation, cDNA Synthesis, and quantitative real time polymerase chain reaction were
performed as previously described 6. RNA was extracted isolated using the Purelink RNA mini kit
(Thermo Fisher Scientific, Waltham, MA, USA). Using Superscript Vilo cDNA synthesis kit
(Thermo Fisher Scientific, Waltham, MA, USA), cDNA was reverse transcribed from 1 μg of total
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RNA. Real-Time PCR was performed using the following probes: OPA1 (Mm01349709_m1),
BNIP3 (Mm01275600_g1), and 18S (Mm03928990_g1)

16

. Final quantification of the relative

quantification of mRNA abundance was calculated using the ∆∆Ct method.

Statistical Analysis
All data was analyzed by Two-way ANOVA (genotype X leucine supplementation) to determine
significant main effects and interactions. A Two-way Repeated Measures ANOVA was performed
on the longitudinal body weight data. A non-paired T-test was used to determine differences in
polyp counts in the APCMin/+ groups. Post-hoc analysis via the Newman-Keuls test was performed.
Significance was established at an alpha level of 0.05.
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CHAPTER V
RESULTS
Body Mass and Polyp Counts
There was a main effect (p = 0.0077) of leucine to decrease body weight independent of genotype,
a main effect (p = 0.0001) of time to increase body weight, and an interaction between genotype
and time (p = 0.0004) (Figure 3). There were no significant differences in the final body weights.
However, there was a trend in the decreased body weight of the APCMin/+ group (p = 0.067) and a
trend in the interaction between genotype and leucine treatment (p = 0.065) in the final body weight
data (Figure 4). Polyps were counted in the colons of each mouse to confirm the genotype of either
wild-type or APCMin/+. As expected, the wild type mice had an average of 0 polyps, while the
APCMin/+ groups averaged between 20-30 polyps (Figure 5).

Tissue Weights
There were no statistically significant differences in tissue weights between groups. Table 1
displays this data. The spleen was enlarged, on average, in the APCMin/+ groups (p = 0.082) but
this difference was not significant (Figure 6). The heart in both leucine treatment groups was, on
average, smaller in weight (p = 0.095), but this difference was also not significant.

Mitochondrial Markers
The gastrocnemius muscle was used in analysis of mRNA abundance of mitochondrial markers
(Figure 7). There were no significant differences between groups of mRNA abundances. Both
APCMin/+ groups had lower average levels of OPA1 compared to the wild-type groups (p = 0.076).
For BNIP3 mRNA abundance, the APCMin/+ no leucine group had the lowest abundance of the 4
groups. The BNIP3 abundance in the APCMin/+ leucine group, however, was similar to those of
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both wild-type groups. There was a trend towards an interaction between genotype and treatment
for BNIP3 abundance (p = 0.055) (Figure 8, Figure 9).

Force Data
There was no statistically significant difference between torque frequencies when analyzing the
electrophysiology data for the mice in each group (Figure 10). The average peak torque for each
group was calculated and compared to the other groups. There was a significant interaction
between genotype and treatment (p = 0.04) in peak torque, and the comparison between the wildtype no leucine group, and APCMin/+ no leucine group was significant. There was a trend of leucine
increasing force production in the wild-type groups (p = 0.06) (Figure 11).
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CHAPTER VI
DISCUSSION

The primary purpose of this study was to see how a leucine supplementation effected the
mitochondrial quality of female APCMin/+ mice in the pre-cachectic state compared to healthy,
female mice. Data on tissue sizes, body weight, and muscle strength were also collected to provide
further insight into how leucine effected the mice. Leucine is commonly used in protein
supplements and has been shown to help stimulate skeletal muscle synthesis in healthy
individuals3,4. So, it was assumed it could help slow muscle atrophy in cancer patients. However,
preliminary data from our laboratory has suggested that a leucine supplementation may exacerbate
muscle atrophy in male cancer individuals rather than help them. This study was done to
investigate if this trend continued in females and how early this may start. We showed that leucine
did not have a significant effect on mitochondrial markers between pre-cachectic wild type and
APCMin/+ mice. The mitochondria are critical organelles that provide the power, via ATP, for a cell
to live and function. When the mitochondria are damaged, the cell is not able to properly function6.
In this study, two mitochondria markers were used to determine the mitochondria health in the
mice. The two markers were OPA1 and BNIP3. OPA1 is a marker for mitochondrial fusion, and
BNIP3 is a marker for mitophagy 6. While there were no significant differences in the levels of
each marker between groups, there was a trend of OPA1 (p = 0.076) being downregulated in both
APCMin/+ groups, with the APCMin/+ leucine group being downregulated the most. This indicates
that the APCMin/+ mice have less mitochondrial fusion 6, and while it wasn’t a significant
difference, leucine may play a role in downregulating that process even further. BNIP3 marker
abundance didn’t have any significant differences but trended towards a possible interaction

22

between genotype and leucine treatment (p = 0.055). The lack of significant differences in the
results could be because these mice were pre-cachectic, so muscle atrophy hadn’t begun yet.
There was a main effect of leucine on body weight (p = 0.0077), as the mice on leucine
were smaller on average. This difference is interesting because leucine is seen as a supplement that
is taken to stimulate skeletal muscle synthesis, and subsequently increase body weight. However,
this data indicates that a leucine supplementation depresses the body weight in female mice. The
potential cause of this is unknown though and further research would be needed. A leucine
treatment did tend to increase force production in the wild-type mice (p = 0.06) when looking at
the peak torque data, supporting the idea that leucine stimulates skeletal muscle growth in healthy
individuals6. This trend was lost in the APCMin/+ group, though, and it is not known why the
APCMin/+ no leucine group had a significantly higher peak torque than the wild-type no leucine
group. Further research would be needed to understand this and see if this significance continued
in female mice in the cachectic stage. The main effect of time (p = 0.0001) was expected because
the mice were growing to reach their final weight. There was also a significant interaction between
genotype and timepoint (p = 0.0004), which was also expected as the APC mice should not grow
as the wild type mice do as they near the cachectic state. There was a trend towards an interaction
between genotype and treatment (p = 0.065), which could indicate the potential effects of leucine
in healthy versus non-healthy individuals. Data from female mice in the cachectic stage would be
needed to confirm this trend though. The lack of significant interaction, in this study, between
leucine and genotype is most likely because these mice had not reached the cachectic stage yet, so
muscle atrophy had not begun and the conclusion of a significant effect of leucine in pre-cachexia
cannot be drawn. There were also no significant findings in the tissue weights between the four
groups, which is most likely the result of the mice being in the pre-cachectic stage as well. The
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trends of the enlarged spleen in the APCMin/+ groups and smaller hearts in the leucine treatment
groups, could be of interest if more longitudinal data was available to confirm these trends.
The average polyp count between the two APCMin/+ groups is something to note. Though
it was not a significant difference (p = 0.75), the average polyp count for the APCMin/+ leucine
group was about 10 higher than the average polyp count for the APCMin/+ no leucine group. This
finding could eventually support the preliminary data that a leucine supplementation exacerbates
the cancer in individuals. However, given that there was no significant difference between groups
in the pre-cachectic stage, this claim cannot be supported and further data looking at the
longitudinal effects would be needed to confirm this. Because there were no significant differences
between the wild-type and APCMin/+ groups, despite this higher polyp count, this also brings forth
the idea of females potentially being protected from the physical effects of leucine. The more
polyps a mouse has, the more the mouse should exhibit physical symptoms of the illness such as
lower body weight or higher mitophagy (BNIP3) markers. Since neither of these were found to be
significant in the APCMin/+ leucine group, despite having the highest average polyp count, this
could indicate that females are more protected than their male counterparts, but further
investigation would need to be done to confirm this and understand what could be causing it.
In conclusion, a leucine supplementation does not have any significant effects on female
mice in the pre-cachectic stage. While the data doesn’t support a leucine supplementation helping
slow or prevent muscle atrophy, the data also doesn’t indicate that a leucine supplementation
exacerbates muscle atrophy as was seen in male mice in preliminary data. The mitochondrial
quality between the wild-type and APCMin/+ groups did not differ significantly, indicating that
leucine has no significant effect on mitochondrial health on females before cachexia. Because there
were some trends observed in the data, though, future studies should focus on female mice in the
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cachectic stage to see if these trends become significant. The lack of significant differences in this
pre-cachectic data also introduces the idea that females may be sheltered against the significant
effects of leucine, unlike their male counterparts. This would be a topic that future studies could
focus on to better understand if this idea is true and begin to understand why this difference exists
between males and females.
While this study yielded interesting results, there were some limitations. One being that
our “n” for each females group was low, and slightly uneven. This could have potentially skewed
data or made trends appear that may not otherwise be there with a higher “n” for each group.
Another limitation is that male data was not included because we were not able to achieve an
adequate “n” for each group of males in time. This lack of opposite sex data limits generalizability
of the results. A third limitation is that this study only focused on the pre-cachectic stage and did
not include data on females in the cachectic stage, which is needed to draw more accurate
conclusions about the effects of leucine. Despite these limitations, this study provides a solid
footing for future studies to build off and better understand how leucine effects individuals with
cancer cachexia. This information is one step closer to potentially helping patients find relief who
are experiencing cancer cachexia and continue moving towards a treatment for this devastating
condition.
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CHAPTER VII
FIGURES AND TABLES

Table 1- Compilation of average tissue weights with standard error.

Figure 3- Average body weight over time per group.

Figure 5- Average polyp count per group with standard
error.

Figure 4- Final body weight comparison with standard
error.

Figure 6- Comparison of average spleen weight with
standard error.
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Figure 7- Comparison of average gastrocnemius weight with
standard error.

Figure 8- Average OPA1 abundance per group normalized
to 18s with standard error.

Figure 9- Average BNIP3 abundance per group normalized
to 18s with standard error.

Figure 10- Average torque frequency per group.

Figure 11- Average peak torque per group with standard
error.
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